SLC2A5 and acute myeloid leukemia: Expression of SLC25A5, which encodes GLUT5, is associated with poor AML patient outcome and pharmacological inhibition of GLUT5 eliminates leukemic phenotypes and potentiates the effect of cytarabine in vivo [113].